At a glance

ClinicalIndex Comparison Record

N/ACompleted· 117 enrolled

Drug / intervention

using serum periostin and eotaxin-2 level +1 moreother

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03207620

NCT03207620N/ACompleted

Compare CT.gov

Interrelation Between Bronchial Asthma and Smoking

Assiut University·observational·Posted Jul 5, 2017·Updated Jan 11, 2022

In Brief

An observational study evaluating using serum periostin and eotaxin-2 level and airway corticosteroid sensitivity for Bronchial Asthma. Completed, enrolled 117 participants across 1 site.

Detailed Summary

Smoking occurs frequently in patients with asthma. Recent surveys on smoking prevalence report 21-26% current smokers in populations of patients with asthma. Detrimental effects of active smoking in asthma include worse asthma control, an impaired response to corticosteroids and accelerated lung function decline.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsBronchial Asthma

CountriesEgypt

Collaborators--

Timeline

N/ACompletedFinished

201820192020202120222023202420252026

First PostedJul 2017

Enrollment StartAug 2018

Primary CompletionAug 2021

Study CompletionAug 2021

TodayJul 2026

First PostedJul 5, 2017

Enrollment StartAug 9, 2018

Primary CompletionAug 1, 2021

Study CompletionAug 10, 2021

TodayJul 2, 2026

Enrollment to primary: 3.0 yearsPosted 9.0 years ago

Interventions

using serum periostin and eotaxin-2 levelother

collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits. each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.

airway corticosteroid sensitivityother

each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.